Dietary supplements are a big business. The industry made almost US$39 billion in revenue in 2022, and with very little regulation and oversight, it stands to keep growing.
Feb 6, 2024
0
12
Following pharmaceutical company Eli Lilly's announcement of the launch of an online portal to connect consumers to its anti-obesity drugs, interest in weight loss medication has spiked, taking the internet by storm.
Jan 22, 2024
0
1
Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news. They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for ...
Jan 17, 2024
0
2
Tejocote weight-loss supplements sold through online through Amazon or Etsy could contain a highly toxic substance, the U.S. Food and Drug Administration is warning.
Jan 5, 2024
0
1
The U.S. Food and Drug Administration is investigating reports of additional dangers linked to several wildly popular weight-loss drugs.
Jan 4, 2024
0
18
Despite the effectiveness of the newer generation of anti-obesity drugs—called GLP-1 receptor agonists—few can tolerate them in the long run. A new study, published in the journal Obesity, reveals that of people prescribed ...
Dec 24, 2023
0
1
America's Poison Centers reported nearly 3,000 calls this year involving the weight loss drug semaglutide—a 15-fold increase since 2019, according to CNN.
Dec 14, 2023
0
0
UK organizations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law, reveals an investigation published by The ...
Dec 13, 2023
0
12
The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday.
Dec 6, 2023
0
3
Wegovy, Mounjaro, Ozempic... These new drugs drawing such intense attention have raised the hopes of millions around the world suffering from diabetes or obesity. But what are they, how are they used and who makes them?
Dec 4, 2023
0
0
